Is it better for Oxford Nanopore to optimize for lower per-base sequencing costs or invest in expanding our range of applications?

Introduction

The trade-off between optimizing for lower per-base sequencing costs and expanding Oxford Nanopore's range of applications presents a critical strategic decision. This scenario involves balancing immediate cost efficiencies against long-term market expansion. I'll analyze this trade-off by examining the product context, potential impacts, key metrics, and experimental approaches to inform a data-driven recommendation.

Step 1

Clarifying Questions (3 minutes)

• Based on our current market position, I'm thinking cost reduction might be crucial for maintaining competitiveness. Could you share how our per-base costs compare to major competitors like Illumina or PacBio?

Why it matters: Helps assess the urgency of cost optimization Expected answer: We're slightly higher but closing the gap Impact on approach: If competitive, might lean towards application expansion

• Considering our revenue model, I assume we have a razor-and-blades approach with device sales and consumables. Is this correct, and what's the revenue split between hardware and consumables?

Why it matters: Informs which area (cost or applications) might have a larger revenue impact Expected answer: 30% hardware, 70% consumables Impact on approach: High consumables revenue might favor cost reduction

• Looking at our user segments, I'm curious about the distribution between research, clinical, and industrial applications. Can you provide a rough breakdown?

Why it matters: Helps identify which segments might benefit most from new applications Expected answer: 60% research, 30% clinical, 10% industrial Impact on approach: Low industrial usage might suggest opportunity for expansion

• Regarding our technical capabilities, how scalable is our current sequencing technology for new applications? Are there any major bottlenecks?

Why it matters: Assesses feasibility of expanding applications Expected answer: Scalable, but some applications require significant R&D Impact on approach: High scalability might favor application expansion

• Considering our current resources, what's our R&D capacity for developing new applications versus optimizing existing technology?

Why it matters: Determines our ability to pursue both strategies simultaneously Expected answer: 70% allocated to optimization, 30% to new applications Impact on approach: Limited new application resources might favor cost optimization